Defence Therapeutics (DTCFF) has received USPTO Notice of Allowance for patent application 18/351,291 covering next-generation antibody-drug conjugate (ADC) technology. The patent, valid until 2043, includes composition-of-matter claims for therapeutically active ADCs and their use in treating diseases like cancer. The company's Accum-based ADCs have shown enhanced intracellular delivery and cytotoxic activity in preclinical cancer models compared to conventional ADCs. The technology features antibodies conjugated to innovative constructs with bile acid and nuclear localization signal from RPS17. This adds to Defence's existing patent portfolio, which includes granted patents in the US, Japan, Australia, and Israel, marking their eighth U.S. patent overall.
Defence Therapeutics (DTCFF) ha ricevuto la Notifica di Concessione dall'USPTO per la domanda di brevetto 18/351,291 riguardante la tecnologia di anticorpi coniugati a farmaci (ADC) di nuova generazione. Il brevetto, valido fino al 2043, include rivendicazioni sulla composizione di ADC terapeuticamente attivi e il loro utilizzo nel trattamento di malattie come il cancro. Gli ADC basati su Accum dell'azienda hanno dimostrato una maggiore capacit脿 di consegna intracellulare e attivit脿 citotossica in modelli preclinici di cancro rispetto agli ADC convenzionali. La tecnologia prevede anticorpi coniugati a costrutti innovativi contenenti acido biliare e un segnale di localizzazione nucleare derivato da RPS17. Questo si aggiunge al portafoglio brevetti esistente di Defence, che include brevetti concessi negli Stati Uniti, Giappone, Australia e Israele, segnando l'ottavo brevetto statunitense complessivo.
Defence Therapeutics (DTCFF) ha recibido el Aviso de Aprobaci贸n de la USPTO para la solicitud de patente 18/351,291 que cubre la tecnolog铆a de conjugados anticuerpo-f谩rmaco (ADC) de pr贸xima generaci贸n. La patente, v谩lida hasta 2043, incluye reivindicaciones sobre la composici贸n de ADCs terap茅uticamente activos y su uso en el tratamiento de enfermedades como el c谩ncer. Los ADCs basados en Accum de la compa帽铆a han demostrado una mayor entrega intracelular y actividad citot贸xica en modelos precl铆nicos de c谩ncer en comparaci贸n con los ADCs convencionales. La tecnolog铆a presenta anticuerpos conjugados a construcciones innovadoras que incluyen 谩cido biliar y una se帽al de localizaci贸n nuclear derivada de RPS17. Esto se suma al portafolio de patentes existente de Defence, que incluye patentes otorgadas en EE. UU., Jap贸n, Australia e Israel, marcando su octava patente estadounidense en total.
Defence Therapeutics (DTCFF) a re莽u un avis d'acceptation de l'USPTO pour la demande de brevet 18/351,291 couvrant une technologie de conjugu茅s anticorps-m茅dicaments (ADC) de nouvelle g茅n茅ration. Le brevet, valable jusqu'en 2043, comprend des revendications sur la composition de mati猫res des ADC th茅rapeutiquement actifs et leur utilisation dans le traitement de maladies telles que le cancer. Les ADC bas茅s sur Accum de la soci茅t茅 ont montr茅 une meilleure d茅livrance intracellulaire et une activit茅 cytotoxique accrues dans des mod猫les pr茅cliniques de cancer par rapport aux ADC conventionnels. La technologie comprend des anticorps conjugu茅s 脿 des structures innovantes avec un acide biliaire et un signal de localisation nucl茅aire provenant de RPS17. Cela s'ajoute au portefeuille de brevets existant de Defence, qui comprend des brevets d茅livr茅s aux 脡tats-Unis, au Japon, en Australie et en Isra毛l, marquant ainsi leur huiti猫me brevet am茅ricain au total.
Defence Therapeutics (DTCFF) hat vom USPTO die Mitteilung 眉ber die Zulassung f眉r die Patentanmeldung 18/351,291 erhalten, die eine Technologie der n盲chsten Generation f眉r Antik枚rper-Wirkstoff-Konjugate (ADC) abdeckt. Das Patent, g眉ltig bis 2043, umfasst Zusammensetzungsanspr眉che f眉r therapeutisch aktive ADCs und deren Einsatz zur Behandlung von Krankheiten wie Krebs. Die auf Accum basierenden ADCs des Unternehmens zeigten in pr盲klinischen Krebsmodellen eine verbesserte intrazellul盲re Abgabe und zytotoxische Aktivit盲t im Vergleich zu herk枚mmlichen ADCs. Die Technologie umfasst Antik枚rper, die an innovative Konstrukte mit Gallens盲ure und einem Kernlokalisationssignal von RPS17 gekoppelt sind. Dies erg盲nzt das bestehende Patentportfolio von Defence, zu dem bereits erteilte Patente in den USA, Japan, Australien und Israel geh枚ren, und markiert das insgesamt achte US-Patent.
Positive
Patent protection until 2043 provides long-term market exclusivity for ADC technology
Enhanced preclinical performance compared to conventional ADCs in cancer models
Broad patent coverage including composition-of-matter claims and therapeutic applications
Expanding patent portfolio across multiple jurisdictions strengthens IP position
Negative
Technology still in preclinical stage, requiring significant development before commercialization
Pending patent applications in key markets like Canada and Europe create uncertainty
Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug delivery technologies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its U.S. patent application covering one of its next-generation antibody-drug conjugate (ADC) technologies. The allowance of U.S. patent application no. 18/351,291 ('291) includes valuable composition-of-matter claims broadly covering therapeutically active ADCs - not limited to individual diseases or therapeutic targets - as well as claims covering the use of ADCs for treating or diagnosing diseases such as cancer.
Defence's Accum®-based ADCs have demonstrated enhanced intracellular delivery and cytotoxic activity in multiple preclinical cancer models compared to conventional ADCs. Upon grant, the '291 patent application will provide the Company with potential market exclusivity until 2043 for its proprietary second-generation Accum®-based ADCs, which include antibodies conjugated to innovative new constructs featuring a bile acid conjugated to a nuclear localization signal (NLS) derived from the ribosomal protein eS17 (RPS17).
This milestone builds on Defence's established patent portfolio for its foundational Accum® technology, which includes granted patents in the United States (US 11,352,437), Japan (JP 7,126,956), Australia (AU 2017233725), and Israel (IL 261765), with applications currently pending in Canada and Europe.
"Second-generation Accum®-based ADCs represent a significant advancement in both oncotherapy and targeted drug delivery," said Sébastien Plouffe, CEO and Founder of Defence Therapeutics. "This recent allowance underscores the innovation and versatility embedded in our ADC platform technology and reflects our commitment to developing novel, effective cancer treatments that push the boundaries of current ADC technologies."
This newly allowed U.S. patent application is poised to become the eighth granted U.S. patent in Defence's expanding portfolio, which now comprises seven published patent families.
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer.
For further information: Sebastien Plouffe, President, CEO and Director P: (514) 947-2272 [email protected]
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit
FAQ
What is the significance of Defence Therapeutics' (DTCFF) new patent allowance?
The patent allowance provides market exclusivity until 2043 for Defence's next-generation ADC technology, covering both composition-of-matter and therapeutic applications for cancer treatment.
How does Defence Therapeutics' Accum-based ADC technology perform compared to conventional ADCs?
According to preclinical studies, Defence's Accum-based ADCs demonstrate enhanced intracellular delivery and superior cytotoxic activity compared to conventional ADCs in multiple cancer models.
What is the current patent portfolio status of Defence Therapeutics (DTCFF)?
Defence has granted patents in the US, Japan, Australia, and Israel, with this new allowance becoming their eighth US patent. Applications are pending in Canada and Europe.
What unique features does Defence Therapeutics' new ADC technology include?
The technology features antibodies conjugated to innovative constructs containing bile acid and a nuclear localization signal derived from the ribosomal protein eS17 (RPS17).
When will Defence Therapeutics' (DTCFF) new ADC patent expire?
The patent will provide market exclusivity until 2043, protecting Defence's proprietary second-generation Accum-based ADC technology.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
